Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

March 21, 2025

Study Completion Date

March 21, 2025

Conditions

Vaccine-Preventable DiseasesHerpes Zoster

Interventions

BIOLOGICAL

CVI-VZV-001

Investigational Product

BIOLOGICAL

Shingrix

Investigational Product

Trial Locations (2)

RECRUITING

Bundang CHA General Hospital, Seongnam-si

RECRUITING

The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul

All Listed Sponsors

lead

CHA Vaccine Institute Co., Ltd.

INDUSTRY